Abstract
BACKGROUND: Hypoxia is a common symptom of lung cancer. Proliferation and neovascularization mediated by hypoxia-inducible factors (HIF) influence several adaptations. It has recently been established that naringenin (NAR) and its nanoparticles are chemo-preventive flavonoids in lung cancer. AIM: Adjust HIF activity by reviving oxygen-sensing enzyme activity while considering possible therapeutic targets. METHOD: The bindings of NAR to target proteins were examined using computational modeling techniques. Additionally, NAR nanoparticles (NARNPs) were synthesized and characterized. Normal fibroblast cells and A549 cells were used to determine cytotoxicity. Colorimetric analysis of α-ketoglutarate detection for hydroxylases. RESULTS: According to molecular modeling, NAR and target proteins have a high affinity. The PHD and FIH activities in A549 are significantly stimulated. CONCLUSION: NAR and NARNPs diminish hypoxia in lung cancer by stimulating oxygen-sensing hydroxylases.